We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Pseudomonas aeruginosa: Multi-Drug-Resistance Development and Treatment Options

Georgios Meletis and Maria Bagkeri

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/55616>

1. Introduction

Antibiotic resistance is a worldwide problem of major importance. Isolations in some countries of multi-drug-resistant (resistant to three or more classes of antimicrobials), extensively-drug-resistant (resistant to all but one or two classes) or even pan-drug-resistant (resistant to all available classes) Gram-negative pathogens are causing therapeutic problems and- in the same time- are posing infection control issues in many hospitals. In fact, numerous studies highlight the link between multi-drug-resistance and increased morbidity and mortality, increased length of hospital stay and higher hospital costs [1-4].

Pseudomonas aeruginosa is a Gram-negative opportunistic nosocomial pathogen responsible for a wide range of infections that may present high rates of antimicrobial resistance. The genome of this microorganism is among the largest in the bacterial world allowing for great genetic capacity and high adaptability to environmental changes. In fact, *P. aeruginosa* has 5567 genes encoded in 6.26 Mbp of DNA while *Escherichia coli* K12 for example has 4279 genes encoded in 4.46 Mbp and *Haemophilus influenzae* Rd has 1.83 Mbp encoding 1714 genes [5]. This large genetic armamentarium- that can be further enriched with the addition of genes acquired by transferable genetic elements via horizontal gene transfer- is a major contributing factor to its formidable ability to develop resistance against all known antibiotics.

Generally, antibiotic resistance mechanisms of *P. aeruginosa* can be divided in intrinsic and acquired. Intrinsic refers to resistance that is a consequence of a large selection of genetically-encoded mechanisms and acquired refers to resistance that is achieved via the acquisi-

tion of additional mechanisms or is a consequence of mutational events under selective pressure.

2. Intrinsic resistance of *Pseudomonas aeruginosa*

P. aeruginosa shows inherent resistance to antimicrobial agents through a variety of mechanisms: (1) decreased permeability of the outer membrane, (2) efflux systems which actively pump antibiotics out of the cell, and (3) production of antibiotic-inactivating enzymes [6].

2.1. Outer membrane permeability

The outer membrane of Gram-negative bacteria is a barrier which prevents large hydrophilic molecules to pass through it. Aminoglycosides and colistin interact with lipopolysaccharides changing the permeability of the membrane in order to pass whereas beta-lactams and quinolones need to diffuse through certain porin channels.

Bacteria produce two major classes of porins: general; which allow almost any hydrophilic molecule to pass [7] and specific; which have binding sites for certain molecules, allowing them to be oriented and pass in the most energy-efficient way [8].

Most bacteria possess lots of general porins and relatively few specific ones. However, the exact opposite occurs for *P. aeruginosa* that expresses mainly specific porins [7].

2.2. Efflux systems

P. aeruginosa expresses several efflux pumps that expel drugs together with other substances out of the bacterial cell. These pumps consist of three proteins: (1) a protein transporter of the cytoplasmic membrane that uses energy in the form of proton motive force, (2) a periplasmic connective protein, and (3) an outer membrane porin [5].

Most antibiotics- except polymyxins- are pumped out [9,10] by these efflux systems (Table 1) therefore their first two components are named multidrug efflux (Mex) along with a letter (e.g. MexA and MexB). The outer membrane porin is called Opr along with a letter (e.g. OprM) [11].

2.3. Antibiotic-inactivating enzymes

P. aeruginosa belongs to the SPICE group of bacteria (*Serratia* spp., *P. aeruginosa*, Indole positive *Proteus*, *Citrobacter* spp., *Enterobacter* spp.). These microorganisms share a common characteristic: the ability to produce chromosomal-encoded and inducible AmpC beta-lactamases. These are cephalosporinases that hydrolyze most beta-lactams and are not inhibited by the beta lactamase inhibitors.

Another endogenous beta-lactamase produced by *P. aeruginosa* is the class D oxacillinase PoxB [12,13]. This enzyme however has only been found in laboratory mutants and is not clinically significant.

Efflux system	Efflux pump family	Substrates	References
MexAB-OprM	Resistance Nodulation Division (RND)	Fluoroquinolones Aminoglycosides β -Lactams (preferably Meropenem, Ticarcillin) Tetracycline Tigecycline Chloramphenicol	[17]
MexCD-OprJ	Resistance Nodulation Division (RND)	Fluoroquinolones β -Lactams (preferably Meropenem, Ticarcillin) Tetracycline Tigecycline Chloramphenicol Erythromycin Roxythromycin	[17]
MexEF-OprN	Resistance Nodulation Division (RND)	Fluoroquinolones β -Lactams (preferably Meropenem, Ticarcillin) Tetracycline Tigecycline Chloramphenicol	[17] [18]
MexXY-OprM	Resistance Nodulation Division (RND)	Fluoroquinolones Aminoglycosides β -Lactams (preferably Meropenem, Ticarcillin, Cefepime) Tetracycline Tigecycline Chloramphenicol	[17]
AmrAB-OprA	Resistance Nodulation Division (RND)	Aminoglycosides	[19]
PmpM	Multidrug And Toxic compound Extrusion (MATE)	Fluoroquinolones	[17]
Mef(A)	Major Facilitator Superfamily (MFS)	Macrolides	[20]
ErmE _{PAF}	Small Multidrug Resistance (SMR)	Aminoglycosides	[21]

Table 1. Efflux systems of *P. aeruginosa*.

3. Antipseudomonal treatment

Despite the intrinsic resistance of *P. aeruginosa* to many antimicrobials, some antibiotics are active against this microorganism [14]. Those used more frequently belong to three antibiotic classes: (1) Beta-lactams, (2) Quinolones and (3) Aminoglycosides (Table 2).

3.1. Beta-lactams

Beta-lactams bind to and inactivate penicillin-binding proteins (PBPs) that are transpeptidases involved in bacterial cell wall synthesis [15]. The group of beta-lactam antibiotics includes penicillins, cephalosporins, monobactams and carbapenems. The beta-lactams that are most active against *P. aeruginosa* are: Piperacillin and ticarcillin (penicillins), ceftazidime (3rd generation cephalosporin), cefepime (4th generation cephalosporin), aztreonam (monobactam), imipenem, meropenem and doripenem (carbapenems).

3.2. Quinolones

Quinolones are synthetic antimicrobials that block DNA replication by inhibiting the activity of DNA gyrase and topoisomerase IV [16]. The fluorquinolones with anti-pseudomonal activity are ciprofloxacin, levofloxacin and ofloxacin.

Antibiotic Class	Mechanism of action	Drug
Penicillins	Bacterial cell wall synthesis inhibition	Ticarcillin
Penicillin / Beta-lactamase inhibitor	Bacterial cell wall synthesis inhibition	Ticarcillin/Clavulanic acid
		Piperacillin/Tazobactam
Cefalosporins	Bacterial cell wall synthesis inhibition	Ceftazidime
		Cefepime
Monobactams	Bacterial cell wall synthesis inhibition	Aztreonam
Carbapenems	Bacterial cell wall synthesis inhibition	Imipenem
		Meropenem
		Doripenem
Fluoroquinolones	Block of DNA synthesis	Ciprofloxacin
		Levofloxacin
		Ofloxacin
Aminoglycosides	Protein synthesis inhibition	Gentamycin
		Tobramycin
		Amikacin

Table 2. Commonly used anti-pseudomonal drugs.

3.3. Aminoglycosides

Aminoglycosides inhibit protein synthesis by binding to the 30S or 50S ribosomal subunit [22]. Drugs of this antibiotic class that can be used against *P. aeruginosa* are tobramycin, amikacin and gentamicin. Aminoglycosides are associated with ototoxicity and nephrotoxicity [23]. Because of these adverse effects and because of their narrow therapeutic range, aminoglycosides are used in combination with agents belonging to other antibiotic classes. The only treatment in which aminoglycosides are recommended as monotherapy is that of urinary tract infections due to *P. aeruginosa* [14].

4. Acquired resistance of *Pseudomonas aeruginosa*

Apart from being resistant to a variety of antimicrobial agents, *P. aeruginosa* develops resistance to anti-pseudomonal drugs as well. This acquired resistance is a consequence of mutational changes or the acquisition of resistance mechanisms via horizontal gene transfer and can occur during chemotherapy [24]. Mutational events may lead to over-expression of endogenous beta-lactamases or efflux pumps, diminished expression of specific porins and target site modifications while acquisition of resistance genes mainly refers to transferable beta-lactamases and aminoglycoside-modifying enzymes (Table 3).

Resistance to	Resistance mechanism
Beta-lactams	Endogenous beta-lactamases
	Acquired beta-lactamases
	Efflux
	Diminished permeability
Fluoroquinolones	Target site mutations
	Efflux
Aminoglycosides	Aminoglycoside-modifying enzymes
	Efflux
	16S rRNA methylases
Polymyxins	LPS modification

Table 3. Resistance mechanisms of *P. aeruginosa* to anti-pseudomonal drugs.

4.1. Resistance to beta-lactams

Resistance to beta-lactam antibiotics is multi-factorial but is mediated mainly by inactivating enzymes called beta-lactamases. These enzymes cleave the amide bond of the beta-lactam ring causing antibiotic inactivation and are classified according to a structural [25] and a functional [26] classification.

Among the beta-lactams, carbapenems are the most efficient against *P. aeruginosa*. These agents are stable to the hydrolytic effect of the majority of the beta-lactamases including the Extended Spectrum Beta-Lactamases (ESBLs) [27]. For this reason, the enzymes that possess carbapenemase activity, namely the carbapenemases [28], will be discussed separately in this section.

4.1.1. Expression of endogenous beta-lactamases

Resistance to beta-lactams in clinical isolates is commonly due to the presence of AmpC beta-lactamases [29-36]. Furthermore, the production of AmpC beta-lactamases in *P. aeruginosa* can be induced by a number of beta-lactam antibiotics such as benzyl penicillins, narrow spectrum cephalosporins and imipenem [37]. In fact, this mutational derepression is one of the most common mechanisms of resistance to beta-lactams in *P. aeruginosa* [29,32,33,36].

AmpC enzymes are not carbapenemases, they possess however a low potential of carbapenem hydrolysis and their overproduction combined with efflux pumps over-expression and/or diminished outer membrane permeability has been proven to lead also to carbapenem resistance in *P. aeruginosa* [38].

4.1.2. Acquired beta-lactamases

Acquired beta-lactamases are typically encoded by genes which are located in transferable genetic elements such as plasmids or transposons [39] often on integrons [40-49]. Integrons are genetic elements that capture and mobilize genes [50]. Other genetic elements associated with transferable resistance in *P. aeruginosa* are the mobile insertion sequences called ISCR elements [49,51-53].

Different types of transferable beta-lactamases have been found in clinical *P. aeruginosa* isolates around the world (Table 4).

Among them, carbapenemases are of major clinical importance because they inactivate carbapenems together with other beta-lactams. Ambler class A ESBLs hydrolyze penicillins, narrow- and broad-spectrum cephalosporins and aztreonam [54]. Some TEM and SHV enzymes do not possess broad-spectrum cephalosporinase activity and are called restricted-spectrum beta-lactamases. Class D OXA beta-lactamases are a heterogeneous group of enzymes and not all share the same properties. Generally, most of them show a preference for cloxacillin over benzylpenicillin. They confer resistance to amino- and carboxypenicillins and narrow – spectrum cephalosporins even though some of them are ESBLs and a few members of the class present carbapenemase activity [24].

4.1.3. Carbapenemases

P. aeruginosa is the species in which all types of transferable carbapenemases, except SIM-1 [55], have been detected. The class B carbapenemases that bear Zn^{2+} in their active center [56] are the most frequent around the world in *P. aeruginosa* isolates and are called metallo-beta-lactamases (MBLs). They hydrolyse *in vitro* all beta-lactams except aztreonam and are the major cause of high-level carbapenem resistance. Genes that encode MBLs are commonly found as

Ambler molecular class	Bush-Jacoby-Madeiros group	Enzymes	References
A	2b	TEM-1, -2, -90, -110, SHV-1	[57,58]
	2be	PER-1, -2	[10]
		VEB-1, -2, -3	[53]
		TEM-4, -21, -24, -42, -116	[59-62]
		SHV-2a, -5, -12	
		GES/IBC-1, -2, -5, -8, -9	
B	3	BEL	
		LBT 802	
		CTX-M-1, -2, -43	
		PSE-1 (CARB-2), PSE-4	[10]
		(CARB-1), CARB-3, CARB-4, CARB-like, AER-1	[63]
C	2f	KPC-2, -5	[64,65]
D	3	IMP-1, -4, -6, -7, -9, -10, -12, -13, -15, -16, -18, -22	[10] [47] [66-76]
		VIM-1, -2, -3, -4, -5, -7, -8, -11, -13, -15, -16, -17, -18	
		SPM-1	
		GIM-1	
		AIM-1	
D	1	NDM-1	
		AmpC	[77]
		OXA	[10]
		LCR-1	[12]
		NPS-1	[54]
D	2d		[57]
			[78-80]

Table 4. Beta-lactamases found in *P. aeruginosa* isolates.

gene cassettes in integrons and are transferable [42]. Interestingly, more resistance genes for other antibiotic classes can be present in the same integrons contributing thus in the development of a multi-drug resistant phenotype.

IMP and VIM type MBLs were first identified in Japan [81] and Italy [82] respectively and have spread though all continents since then. Other metallo-enzymes are more geographically restricted. SPM-1, after causing outbreaks in Brazil [28], has been found in Basel [83] in a single isolate recovered from a patient previously hospitalized in Brazil. GIM-1 and AIM-1 were

reported from Germany [41] and Australia [84] and did not spread elsewhere. Finally, the only report for NDM-1 in *P. aeruginosa* was made from Serbia [76].

Ambler class A carbapenemase KPC was first reported in *P. aeruginosa* isolates in Colombia [64] but KPC-producing *P. aeruginosa* isolates have not been reported from other continents except Latin America. KPCs present high rates of carbapenem hydrolysis and inactivate all other beta-lactams including aztreonam.

Enzymes GES/IBC belong to the same enzymatic class but their carbapenemase activity is not as high as that of the KPCs. It may become important however if combined with diminished outer membrane permeability or efflux over-expression. For *P. aeruginosa*, GES-2 has been reported in South Africa [85] and IBC-2 in Greece [86].

Class D carbapenemases like OXA-198 have been found in *P. aeruginosa* isolates although such findings are rather rare for this species [87]. The most clinically important carbapenemases are summarized in Table 5.

Ambler molecular class	Bush-Jacoby-Madeiros group	Carbapenemases
A	2f	KPC
B	3	IMP enzymes VIM enzymes SPM-1 GIM-1 AIM-1 NDM-1

Table 5. Clinically important carbapenemases found in *P. aeruginosa* isolates.

4.1.4. Efflux systems over-expression

Among the various efflux systems of *P. aeruginosa*, MexAB-OprM, MexXY-OprM and MexCD-OprJ play an important role in developing beta-lactam resistance [88]. Between these three, MexAB-OprM accommodates the broadest range of beta-lactams [24], is by far the better exporter of meropenem [24] and is most frequently related to beta-lactam resistance in clinical *P. aeruginosa* isolates [33,89]. The efflux pumps may be over-expressed in some isolates [90] contributing thus, together with other mechanisms in the development of multi-drug resistance [24].

4.1.5. Diminished permeability

OprD is a specific porin of the outer membrane of *P. aeruginosa* through which carbapenems (mainly imipenem) enter into the periplasmic space [91]. Diminished expression [92] or mutational loss [93] of this porin is the most common mechanism of resistance to carbapenems [24,94] and is frequently associated with efflux pumps and/or AmpC over-expression [36,38].

Diminished expression or loss of the OprD porin is a frequent phenomenon during imipenem treatment [95].

4.2. Resistance to fluoroquinolones

High-level resistance to fluoroquinolones is mediated by target site modifications. Efflux plays a contributing role as well [96,97] and the two mechanisms often coexist [32,98-100].

4.2.1. DNA gyrase and topoisomerase IV mutations

Gyrase and topoisomerase are comprised by two subunits each. DNA gyrase (GyrA and GyrB) is the main target of fluoroquinolones in *P. aeruginosa*. Consequently, mutations are most common for this enzyme rather than for topoisomerase IV (ParC and ParE) [98-102]. Highly resistant isolates have multiple mutations in *gyrA* and/or *parC* [98,101-103] while mutations regarding the other subunits are less frequently encountered [100-102,104].

4.2.2. Efflux pumps contribution

Four efflux pumps contribute to fluoroquinolone resistance: MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM [105] as a consequence of mutational events in their repressor genes [24]. Among these, MexAB-OprM, MexCD-OprJ, and MexEF-OprN have been associated to fluoroquinolone resistance in clinical isolates [31,105-107] whereas MexXY-OprM has only been linked rarely to such type of resistance [106].

4.3. Resistance to aminoglycosides

Acquired resistance to aminoglycosides is mediated by transferable aminoglycoside-modifying enzymes (AMEs), rRNA methylases and derepression of endogenous efflux systems [24,108,109].

4.3.1. Aminoglycoside-modifying enzymes

Modification and subsequent inactivation of aminoglycosides is achieved by three deferent mechanisms: (1) acetylation, by aminoglycoside acetyltransferases (AACs), (2) adenylation, by aminoglycoside nucleotidyltransferases (ANTs), and (3) phosphorylation, by aminoglycoside posphoryltransferases (APHs) [108].

Genes encoding AMEs are typically found on integrons together with other genes responsible for transferable resistance for other antibiotic classes. This way AMEs become important determinants for the development of multi-drug resistance in *P. aeruginosa* and other species [24,108,109].

Enzymatic families that acetylate the 3 and 6' position of the antibiotic are the most common. Five subfamilies of AAC(3) and two of AAC(6') have been described for *P. aeruginosa*, each one presenting different preferences for aminoglycoside substrates (Table 6).

Among the nucleotidyltransferases, ANT(2')-I is the most frequently encountered in *P. aeruginosa*. This enzyme is present in isolates showing resistance to gentamicin and tobramycin but not to amikacin [109].

Almost all phosphoryltransferases of *P. aeruginosa* act in the 3' position of the aminoglycoside molecule [24]. However, they have less clinical importance because of the fact that they inactivate aminoglycosides that are not routinely used for the treatment of *P. aeruginosa* infections such as kanamycin and neomycin [109]. The enzymes of this family that inactivate anti-pseudomonal aminoglycosides are APH(3')-VI [110-112], APH(3')-IIb-like [113] and APH(2'') [110]. Despite being reported in some cases, these enzymes remain rare for clinical *P. aeruginosa* isolates [24].

4.3.2. Efflux systems

Resistance to aminoglycosides in *P. aeruginosa* can occur independently of aminoglycoside-modifying enzymes in cystic fibrosis patients. This type of resistance has been reported in several studies [99,118-120] and is attributable to over-expression of the MexXY-OprM efflux pump.

4.3.3. 16S rRNA methylases

Methylation of the 16S rRNA of the A site of the 30S ribosomal subunit interferes with aminoglycoside binding and consequently promotes high-level resistance to all aminoglycosides [24]. Different 16S rRNA methylases have been described for *P. aeruginosa*: RmtA [112,121], RmtB [122], ArmA [122,123] and RmtD which is commonly found together with the MBL SPM-1 in Brazil [124,125].

5. Treatment options for MDR *Pseudomonas aeruginosa*

Different combinations of the aforementioned mechanisms may be present in a single *P. aeruginosa* isolate leading to simultaneous resistance to various anti-pseudomonal compounds. The most potent combination is obviously that of a carbapenemase producing isolate usually enriched by resistance to quinolones and aminoglycosides leaving very limited options for antimicrobial treatment.

As far as newer carbapenem compounds are concerned, data suggest that doripenem does not offer advantages over other carbapenems against carbapenemase producing strains [126].

Tigecycline is an option for Gram-negative MDR pathogens but it cannot be used against *P. aeruginosa*, *Morganella morganii*, *Proteus* spp. and *Providencia* spp. because it is intrinsically vulnerable to their chromosomal-encoded efflux pumps [127].

Furthermore, time-kill studies on 12 MBL-producing *P. aeruginosa* isolates performed with aztreonam alone and in combination with ceftazidime and amikacin, showed bactericidal activity against one and eight isolates respectively. In the same study, colistin was bactericidal against all 12 isolates [128].

Category	Enzymatic family	Subfamily	Substrates	References
Acetyltransferases (AAC)	AAC(3)	I	Gentamicin	[11]
		II	Gentamicin	[48]
			Tobramycin	[108,109]
		III	Gentamicin	
			Tobramycin	
		IV	Gentamicin	
		VI	Gentamicin	
			Tobramycin	
	AAC(6')	I	Tobramycin	[108,109]
			Amikacin	
		II	Tobramycin Gentamicin	
Nucleotidyltransferases (ANT)	ANT(2')	I	Gentamicin	[109]
			Tobramycin	
	ANT(4')	IIa	Tobramycin	[114,115]
			Amikacin	
		IIb	Tobramycin	
			Amikacin	
	ANT(3')		Streptomycin	[108]
Phosphoryltransferases (APH)	APH(3')	II	Kanamycin	[109]
			Neomycin	[116]
		IIb	Kanamycin	[117]
		IIb-like	Amikacin	[113]
			(weakly)	
		VI	Amikacin Isepamicin	[110-112]
	APH(2'')		Gentamicin Tobramycin	[110]

Table 6. Aminoglycoside-modifying enzymes found in *P. aeruginosa* isolates.

In fact, polymyxins and colistin in particular, are quite effective in the treatment of MDR *P. aeruginosa* infections [129,130]. The target of colistin is the bacterial cell membrane. More precisely, colistin interacts with the lipid A of lipopolysaccharides, allowing penetration through the outer membrane by displacing Ca^{2+} and Mg^{2+} . The insertion between the phospholipids leads to loss of membrane integrity and consequent bacterial cell death [131]. There are reports of resistance to polymyxin B [132-134] and colistin [135-137] in clinical isolates but they remain to date relatively rare for *P. aeruginosa* [24]. While in many cases the mechanism of clinical polymyxin resistance is unknown, substitution of the lipopolysaccharide lipid A with aminoarabinose has been shown to contribute to polymyxin resistance *in vitro* [138] and

cystic fibrosis isolates [139]. Colistin is frequently associated with nephro- and neurotoxicity but both these adverse effects seem to be dose-dependent and reversible [140].

Another interesting option for the treatment of MDR *P. aeruginosa* is fosfomycin, an old antibacterial that has regained attention because of its *in vitro* activity against such isolates [140]. Fosfomycin inactivates the enzyme pyruvyl-transferase, which is required for the synthesis of the cell wall peptidoglycan. In a review of the existing fosfomycin studies, 81.1% of 1529 patients were successfully treated for infections caused by *P. aeruginosa*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Enterobacter* spp. and *Klebsiella* spp. Fosfomycin was administered together with aminoglycosides, cephalosporins and penicillines [141]. More studies are needed however to determine the future role of fosfomycin against MDR *P. aeruginosa* isolates.

6. Combination therapy

The application of combination therapy instead of monotherapy in cases of non-MDR *P. aeruginosa* remains to date a controversial issue [14]. Combination treatment against MDR strains instead seems to be some times necessary (for example in cases of pan-resistance or resistance to all except a single agent). In such cases better results are expected by the additive or subadditive activity of a combination or by the enhancement of a single active agent by an otherwise inactive drug [142].

Several old and newer studies have showed the increased activity *in vitro* of various antibiotic combinations against MDR *P. aeruginosa* (Table 7) even though, the mechanisms of positive interaction between the various agents are rarely known [142].

Antibiotic combination	References
Ticarcillin, Tobramycin, Rifampin	[143]
Cephalosporins, Quinolones	[144]
Ceftazidime, Colistin	[145]
Macrolides, Tobramycin, Trimethoprim, Rifampin	[146]
Polymyxin B, Rifampin	[147]
Polymyxin B, Imipenem	[148]
Colistin, Meropenem	[149]

Table 7. Enhanced activity of antibiotic combinations against MDR *P. aeruginosa*.

7. Conclusion

P. aeruginosa is a nosocomial pathogen of particular clinical concern not only because of its extraordinary resistance mechanisms armamentarium but also for its formidable ability to

adapt very well to the hospital environment. There are important challenges in the treatment of MDR *P. aeruginosa* strains and their isolation in healthcare settings poses serious infection control issues. For these reasons, the prudent use of antibiotics, mainly those used as last resort treatment like carbapenems is of outmost importance in order to prevent evolutionary pressure that may lead to the emergence of highly resistant clones.

Author details

Georgios Meletis^{1,2} and Maria Bagkeri³

*Address all correspondence to: meletisg@hotmail.com

1 Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece

2 Department of Clinical Microbiology, Veroia General Hospital, Veroia, Greece

3 Department of Internal Medicine, Agios Dimitrios General Hospital of Thessaloniki, Greece

References

- [1] Slama TG. Gram-negative antibiotic resistance: there is a price to pay. *Crit Care* 2008;12. (Sup4) S4.
- [2] Kerr KG, Snelling AM. *Pseudomonas aeruginosa*: a formidable and ever-present adversary. *J Hosp Infect* 2009;73. 338–344.
- [3] Mauldin PD, Salgado CD, Hansen IS, et al. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant Gram-negative bacteria. *Antimicrob Agents Chemother* 2010;54. 109–115.
- [4] Tumbarello M, Repetto E, Trecarichi EM, et al. Multidrug-resistant *Pseudomonas aeruginosa* bloodstream infections: risk factors and mortality. *Epidemiol Infect* 2011;139. 1740–1749.
- [5] Lambert PA. Mechanisms of antibiotic resistance in *Pseudomonas aeruginosa*. *J R Soc Med* 2002;95. 22–26.
- [6] Moore NM, Flaws ML. Antimicrobial resistance mechanisms in *Pseudomonas aeruginosa*. *Clin Lab Sci* 2011; 24. 47–51.
- [7] Hancock REW, & Brinkman F. Function of *Pseudomonas* porins in uptake and eflux. *Annu Rev Microbiol* 2002;56. 17–38.

- [8] Tamber S, Ochs MM, Hancock REW. Role of the novel OprD family of porins in nutrient uptake in *Pseudomonas aeruginosa*. *J Bacteriol* 2006;188. 45-54.
- [9] Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant *Pseudomonas aeruginosa*: Clinical impact and complex regulation of chromosomally encoded resistance mechanisms. *Clin Micro Rev* 2009;22. 582-610.
- [10] Strateva T, Yordanov D. *Pseudomonas aeruginosa* – a phenomenon of bacterial resistance. *J Med Microbiol* 2009;58. 1133–1148.
- [11] Schweizer HP. Efflux as a mechanism of resistance to antimicrobials in *Pseudomonas aeruginosa* and related bacteria: unanswered questions. *Genet Mol Res* 2003;2. 48-62.
- [12] Girlich D, Naas T, Nordmann P. Biochemical characterization of the naturally occurring oxacillinase OXA-50 of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2004;48.2043–2048.
- [13] Kong KF, Jayawardena SR, Del Puerto A, et al. Characterization of *poxB*, a chromosomal-encoded *Pseudomonas aeruginosa* oxacillinase. *Gene* 2005;358. 82–92.
- [14] Moore NM, Flaws ML. Treatment strategies and recommendations for *Pseudomonas aeruginosa* infections. *Clin Lab Sci* 2011;24. 52-56.
- [15] Tipper DJ. Mode of action of beta-lactam antibiotics. *Pharmacol Ther* 1985;27.1-35.
- [16] Hooper DC. Quinolone mode of action--new aspects. *Drugs* 1993;45. 8-14.
- [17] Poole K. Efflux-mediated antimicrobial resistance. *J Antimicrob Chemother* 2005;56. 20–51.
- [18] Kohler T, Van Delden C, Curty LK, et al. Overexpression of the MexEF-OprN multi-drug efflux system affects cell-to-cell signaling in *Pseudomonas aeruginosa*. *J Bacteriol* 2001;183. 5213–5222.
- [19] Westbrook-Wadman S, Sherman DR, Hickey MJ, et al. Characterization of a *Pseudomonas aeruginosa* efflux pump contributing to aminoglycoside impermeability. *Antimicrob Agents Chemother* 2004;43. 2975–2983.
- [20] Pozzi G, Iannelli F, Oggioni MR, et al. Genetic elements carrying macrolide-efflux genes in streptococci. *Curr. Drug Targets Infect Disord* 2004; 4. 203–206.
- [21] Li XZ, Poole K, Nikaido H. Contributions of MexAB-OprM and an ErmE homolog to intrinsic resistance of *Pseudomonas aeruginosa* to aminoglycosides and dyes. *Antimicrob Agents Chemother*, 2003;47. 27–33.
- [22] Dozzo P, Moser, HE. New aminoglycoside antibiotics . *Expert Opin Ther Pat* 2010;20.1321-1341.
- [23] Pagkalis S, Mantadakis E, Mavros MN, et al. Pharmacological considerations for the proper clinical use of aminoglycosides. *Drugs* 2011;71. 2277-2294.

- [24] Poole K. *Pseudomonas aeruginosa*: resistance to the max. *Front Microbiol* 2011;2:65.
- [25] Ambler RP. The structure of beta-lactamases. *Philos Trans R Soc Lond B Biol Sci* 1980;289. 321-331.
- [26] Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. *Antimicrob Agents Chemother* 1995;39. 1211-1233.
- [27] Falagas ME, Karageorgopoulos DEJ. Extended-spectrum beta-lactamase-producing organisms. *J Hosp Infect* 2009;73:345-354.
- [28] Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. *Clin Microbiol* 2007;20. 440-458.
- [29] Arora S, Bal, M. AmpC β -lactamase producing bacterial iso-lates from Kolkata hospital. *Indian J Med Res* 2005;122. 224-233.
- [30] Bratu S, Landman D, Gupta, J, et al. Role of AmpD, OprF and penicillin-binding proteins in β -lactam resistance in clinical isolates of *Pseudomonas aeruginosa*. *J Med Microbiol* 2007;56. 809-814.
- [31] Reinhardt A, Kohler T, Wood P, et al. Development and persistence of antimicrobial resistance in *Pseudomonas aeruginosa*: a longitudinal observation in mechanically ventilated patients. *Antimicrob Agents Chemother* 2007;51. 1341-1350.
- [32] Tam VH, Schilling AN, LaRocco MT, et al. Prevalence of AmpC over-expression in blood-stream isolates of *Pseudomonas aeruginosa*. *Clin Microbiol Infect* 2007;13, 413-418.
- [33] Drissi M, Ahmed ZB, Dehecq B, et al. Antibiotic susceptibility and mechanisms of β -lactam resistance among clinical strains of *Pseudomonas aeruginosa*: first report in Algeria. *Med Mal Infect* 2008;38. 187-191.
- [34] Vettoretti L, Floret N, Hocquet D, et al. Emergence of extensive-drug-resistant *Pseudomonas aeruginosa* in a French university hospital. *Eur J Clin Microbiol Infect Dis* 2009;28. 1217-1222.
- [35] Upadhyay S, Sen MR, Bhattacharjee A. Presence of different β -lactamase classes among clinical isolates of *Pseudomonas aeruginosa* expressing AmpC β -lactamase enzyme. *J Infect Dev Ctries* 2010;4. 239-242.
- [36] Xavier DE, Picao RC, Girardello R, et al. Efflux pumps expression and its association with porin down-regulation and β -lactamase production among *Pseudomonas aeruginosa* causing bloodstream infections in Brazil. *BMC Microbiol* 2010;10. 217.
- [37] Dunne WM Jr, Hardin DJ.J. Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of *Pseudomonas aeruginosa*, *Enterobacter* spp., *Citrobacter* spp., and *Serratia* spp. *Clin Microbiol* 2005;43. 5945-5949.

- [38] Quale J, Bratu S, Gupta J, et al. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of *Pseudomonas aeruginosa* clinical isolates. *Antimicrob Agents Chemother* 2006;50. 1633-1641.
- [39] Giedraitienė A, Vitkauskienė A, Naginienė R, et al. Antibiotic resistance mechanisms of clinically important bacteria. *Medicina (Kaunas)* 2011;47.137-146.
- [40] Poirel L, Nordmann P. Acquired carbapenem-hydrolyzing β -lactamases and their genetic support. *Curr Pharm Biotechnol* 2002; 3. 117-127.
- [41] Castanheira M, Toleman MA, Jones RN, et al. Molecular characterization of a β -lactamase gene, blaGIM-1, encoding a new subclass of metallo- β -lactamase. *Antimicrob Agents Chemother* 2004;48. 4654-4661.
- [42] Walsh TR, Toleman MA, Poirel L, et al. Metallo- β -lactamases: the quiet before the storm? *Clin Microbiol Rev* 2005;18. 306-325.
- [43] Naas T, Aubert D, Lambert T, et al. Complex genetic structures with repeated elements, a sul-type class 1 integron, and the blaVEB extended-spectrum β -lactamase gene. *Antimicrob Agents Chemother* 2006;50. 1745-1752.
- [44] Bogaerts P, Bauraing C, Deplano A, et al. Emergence and dissemination of BEL-1-producing *Pseudomonas aeruginosa* isolates in Belgium. *Antimicrob Agents Chemother* 2007;51. 1584-1585.
- [45] Gupta V. Metallo β -lactamases in *Pseudomonas aeruginosa* and *Acinetobacter* species. *Expert Opin Investig Drugs* 2008;17. 131-143.
- [46] Li H, Toleman MA, Bennett PM, et al. Complete Sequence of p07-406, a 24,179-base-pair plasmid harboring the blaVIM-7 metallo- β -lactamase gene in a *Pseudomonas aeruginosa* isolate from the United States. *Antimicrob Agents Chemother* 2008;52. 3099-3105.
- [47] Castanheira M, Bell JM, Turnidge JD. Carbapenem resistance among *Pseudomonas aeruginosa* strains from India: evidence for nationwide endemicity of multiple metallo- β -lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). *Antimicrob Agents Chemother* 2009;53. 1225-1227.
- [48] Zhao WH, Chen G, Ito R, et al. Relevance of resistance levels to carbapenems and integron-borne blaIMP-1, blaIMP-7, blaIMP-10 and blaVIM-2 in clinical isolates of *Pseudomonas aeruginosa*. *J Med Microbiol* 2009;58. 1080-1085.
- [49] Kotsakis SD, Papagiannitsis CC, Tzelepi E, et al. GES-13, a β -lactamase variant possessing Lys-104 and Asn-170 in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2010;54. 1331-1333.
- [50] Cambray G, Guerout AM, Mazel D. Integrons. *Annu Rev Genet* 2010;44. 141-166.

- [51] Poirel L, Magalhaes M, Lopes M, et al. Molecular analysis of metallo- β -lactamase gene blaSPM-1-surrounding sequences from disseminated *Pseudomonas aeruginosa* isolates in Recife, Brazil. *Antimicrob Agents Chemother* 2004;48. 1406–1409.
- [52] Picao RC, Poirel L, Gales AC, et al. Diversity of β -lactamases produced by ceftazidime-resistant *Pseudomonas aeruginosa* isolates causing bloodstream infections in Brazil. *Antimicrob Agents Chemother* 2009;53. 3908–3913.
- [53] Picao RC, Poirel L, Gales AC, et al. Further identification of CTX-M-2 extended-spectrum β -lactamase in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2009;53. 2225–2226.
- [54] Paterson DL, Bonomo RA. Extended-spectrum β -lactamases: a clinical update. *Clin Microbiol Rev* 2005;18. 657–686.
- [55] Lee K, Yum JH, Yong D, et al. Novel acquired metallo- β -lactamase gene, blaSIM-1, in a class 1 integron from *Acinetobacter baumannii* clinical isolates from Korea. *Antimicrob Agents Chemother* 2005;49. 4485–4491.
- [56] Sacha P, Wieczorek P, Hauschild T, et al. Metallo-beta-lactamases of *Pseudomonas aeruginosa*--a novel mechanism of resistance to beta-lactam antibiotics. *Folia Histochem Cytobiol* 2008;46. 137–142.
- [57] Pai H, Jacoby GA. Sequences of the NPS-1 and TLE-1 β -lactamase genes. *Antimicrob Agents Chemother* 2001;45. 2947–2948.
- [58] Kalai BS, Achour W, Bejaoui M, et al. Detection of SHV-1 β -lactamase in *Pseudomonas aeruginosa* strains by genetic methods. *Pathol Biol (Paris)* 2009;57. e73–75.
- [59] Celenza G, Pellegrini C, Caccamo M, et al. Spread of bla(CTX-M-type) and bla(PER-2) β -lactamase genes in clinical isolates from Bolivian hospitals. *J Antimicrob Chemother* 2006;57. 975–978.
- [60] Jiang X, Zhang Z., Li, M, et al. Detection of extended-spectrum β -lactamases in clinical isolates of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2006;50. 2990–2995.
- [61] Rejiba S, Limam F, Belhadj C. Biochemical characterization of a novel extended-spectrum β -lactamase from *Pseudomonas aeruginosa*. *Microb Drug Resist* 2002;8. 9–13.
- [62] al Naiemi N, Duim B, Bart, A. A CTX-M extended-spectrum β -lactamase in *Pseudomonas aeruginosa* and *Stenotrophomonas maltophilia*. *J Med Microbiol* 2006;55. 1607–1608.
- [63] Sanschagrin F, Bejaoui N, Levesque RC. Structure of CARB-4 and AER-1 carbenicillin-hydrolyzing β -lactamases. *Antimicrob Agents Chemother* 42. 1998;1966–1972.
- [64] Villegas MV, Lolans K, Correa A, et al. First identification of *Pseudomonas aeruginosa* isolates producing a KPC-type carbapenem-hydrolyzing β -lactamase. *Antimicrob Agents Chemother* 2007;51. 1553–1555.

- [65] Wolter DJ, Khalaf N, Robledo IE, et al. Surveillance of carbapenem-resistant *Pseudomonas aeruginosa* isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 β -lactamases. *Antimicrob Agents Chemother* 2009;53. 1660–1664.
- [66] Bert F, Vanjak D, Leflon-Guibout V, et al. IMP-4-producing *Pseudomonas aeruginosa* in a French patient repatriated from Malaysia: impact of early detection and control measures. *Clin Infect Dis* 2007;44. 764–765.
- [67] Ryoo NH, Lee K, Lim JB, et al. Outbreak by meropenem-resistant *Pseudomonas aeruginosa* producing IMP-6 metallo- β -lactamase in a Korean hospital. *Diagn Microbiol Infect Dis* 2009;63. 115–117.
- [68] Iyobe S, Kusadokoro H, Takahashi A, et al. Detection of a variant metallo- β -lactamase, IMP-10, from two unrelated strains of *Pseudomonas aeruginosa* and an *Alcaligenes xylosoxidans* strain. *Antimicrob Agents Chemother* 2002;46. 2014–2016.
- [69] Docquier JD, Riccio ML, Mugnaioli C, et al. IMP-12, a new plasmid-encoded metallo- β -lactamase from a *Pseudomonas putida* clinical isolate. *Antimicrob Agents Chemother* 2003;47. 1522–1528.
- [70] Garza-Ramos U, Morfin-Otero R, Sader HS, et al. Metallo- β -lactamase gene bla(IMP-15) in a class 1 integron, In95, from *Pseudomonas aeruginosa* clinical isolates from a hospital in Mexico. *Antimicrob Agents Chemother* 2008;52. 2943–2946.
- [71] Mendes RE, Toleman MA, Ribeiro J, et al. Integron carrying a novel metallo- β -lactamase gene, blaIMP-16, and a fused form of aminoglycoside-resistant gene aac(6′)-30/aac(6′)-Ib′: report from the SENTRY Antimicrobial Surveillance Program. *Antimicrob Agents Chemother* 2004;48. 4693–4702.
- [72] Duljasz W, Gniadkowski M, Sitter S, et al. First organisms with acquired metallo- β -lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. *Antimicrob Agents Chemother* 2009;53. 2221–2222.
- [73] Koh TH, Wang GC, Sng LH. IMP-1 and a novel metallo- β -lactamase, VIM-6, in fluorescent *Pseudomonads* isolated in Singapore. *Antimicrob Agents Chemother* 2004;48. 2334–2336.
- [74] Siarkou VI, Vitti D, Protonotariou E, et al. Molecular epidemiology of outbreak-related *Pseudomonas aeruginosa* strains carrying the novel variant blaVIM-17 metallo- β -lactamase gene. *Antimicrob Agents Chemother* 2009;53. 1325–1330.
- [75] Toleman MA, Simm AM, Murphy TA, et al. Molecular characterization of SPM-1, a novel metallo- β -lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. *J Antimicrob Chemother* 2002;50. 673–679.
- [76] Jovcic B, Lepsanovic Z, Suljagic V, et al. Emergence of NDM-1 Metallo- β -Lactamase in *Pseudomonas aeruginosa* Clinical Isolates from Serbia. *Antimicrob Agents Chemother* 2011;55. 3929–3931.

- [77] Rodriguez-Martinez JM, Poirel L, Nordmann P. Extended-spectrum cephalosporinases in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2009;53. 1766–1771.
- [78] Giuliani F, Docquier JD, Riccio ML, et al. OXA-46, a new class D β -lactamase of narrow substrate specificity encoded by a blaVIM-1-containing integron from a *Pseudomonas aeruginosa* clinical isolate. *Antimicrob Agents Chemother* 2005;49. 1973–1980.
- [79] Juan C, Mulet X, Zamorano L, et al. Detection of the novel extended spectrum β -lactamase (ESBL) OXA-161 from a plasmid-located integron in *Pseudomonas aeruginosa* clinical isolates in Spain. *Antimicrob Agents Chemother* 2009;53. 5288–5290.
- [80] Sevillano E, Gallego L, Garcia-Lobo JM. First detection of the OXA-40 carbapenemase in *P. aeruginosa* isolates, located on a plasmid also found in *A. baumannii*. *Pathol Biol (Paris)* 2009;57. 493–495.
- [81] Watanabe M, Iyobe S, Inoue M, et al. Transferable imipenem resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 1991;35.147–151.
- [82] Lauretti L, Riccio ML, Mazzariol A, et al. Cloning and characterization of blaVIM, a new integron-borne metallo- β -lactamase gene from a *Pseudomonas aeruginosa* clinical isolate. *Antimicrob Agents Chemother* 1999;43. 1584–1590.
- [83] Salabi AE, Toleman MA, Weeks J, et al. First report of the metallo-beta-lactamase SPM-1 in Europe. *Antimicrob Agents Chemother* 2010;54. 582.
- [84] Yong D, Bell JM, Ritchie B, et al. A novel sub-group metallo- β -lactamase (MBL), AIM-1, emerges in *Pseudomonas aeruginosa* (PSA) from Australia. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 2007; Abstract C1–593.
- [85] Poirel L, Weldhagen GF, Naas T, et al. GES-2, a class A beta-lactamase from *Pseudomonas aeruginosa* with increased hydrolysis of imipenem. *Antimicrob Agents Chemother* 2001;45. 2598–2603.
- [86] Mavroidi A, Tzelepi E, Tsakris A, et al. An integron-associated β -lactamase (IBC-2) from *Pseudomonas aeruginosa* is a variant of the extended-spectrum β -lactamase IBC-1. *J Antimicrob Chemother* 2001;48. 627–630.
- [87] El Garch F, Bogaerts P, Bebrone C, et al. OXA-198, an acquired carbapenem-hydrolyzing class D beta-lactamase from *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2011;55. 4828–4833.
- [88] Poole K. Resistance to β -lactam antibiotics. *Cell Mol Life Sci* 2004;61. 2200–2223.
- [89] Tomas M, Doumith M, Warner M, et al. Efflux pumps, OprD porin, AmpC β -lactamase, and multiresistance in *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. *Antimicrob Agents Chemother* 2010;54. 2219–2224.

- [90] Yoneda K, Chikumi H, Murata T, et al. Measurement of *Pseudomonas aeruginosa* multidrug efflux pumps by quantitative real-time polymerase chain reaction. *FEMS Microbiol Lett* 2005;243. 125-131.
- [91] Farra A, Islam S, Strålfors A, et al. Role of outer membrane protein OprD and penicillin-binding proteins in resistance of *Pseudomonas aeruginosa* to imipenem and meropenem. *Int J Antimicrob Agents* 2008;31. 427-433.
- [92] Gutiérrez O, Juan C, Cercenado E, et al. Molecular epidemiology and mechanisms of carbapenem resistance in *Pseudomonas aeruginosa* isolates from Spanish hospitals. *Antimicrob Agents Chemother* 2007;51. 4329-4335.
- [93] Horii T, Muramatsu H, Morita M, et al. Characterization of *Pseudomonas aeruginosa* isolates from patients with urinary tract infections during antibiotic therapy. *Microb Drug Resist* 2003;9. 223-229.
- [94] Wang J, Zhou JY, Qu TT, et al. Molecular epidemiology and mechanisms of carbapenem resistance in *Pseudomonas aeruginosa* isolates from Chinese hospitals. *Int J Antimicrob Agents* 2010;3. 486-491.
- [95] Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibiotic-resistant *Pseudomonas aeruginosa*: comparison of risks associated with different antipseudomonal agents. *Antimicrob Agents Chemother* 1999;43. 1379-1382.
- [96] Jacoby GA. Mechanisms of resistance to quinolones. *Clin Infect Dis* 2005;41. 120-126.
- [97] Drlica K, Hiasa H, Kerns R, et al. Quinolones: action and resistance updated. *Curr Top Med Chem* 2009;9. 981-998.
- [98] Higgins PG, Fluit AC, Milatovic D, et al. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of *Pseudomonas aeruginosa*. *Int J Antimicrob Agents* 2003;21. 409-413.
- [99] Henrichfreise B, Wiegand I, Pfister W, et al. Resistance mechanisms of multiresistant *Pseudomonas aeruginosa* strains from Germany and correlation with hypermutation. *Antimicrob Agents Chemother* 2007;51. 4062-4070.
- [100] Rejiba S, Aubry A, Petitfrere S, et al. Contribution of parE mutation and efflux to ciprofloxacin resistance in *Pseudomonas aeruginosa* clinical isolates. *J Chemother* 2008;20. 749-752.
- [101] Lee JK, Lee YS, Park YK, et al. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of *Pseudomonas aeruginosa*. *Int J Antimicrob Agents* 2005;25. 290-295.
- [102] Muramatsu H, Horii T, Takeshita A, et al. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant *Pseudomonas aeruginosa*. *Chemotherapy* 2005;51. 70-75.

- [103] Nakano M, Deguchi T, Kawamura T, et al. Mutations in the *gyrA* and *parC* genes in fluoroquinolone-resistant clinical isolates of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 1997;41. 2289–2291.
- [104] Schwartz T, Volkmann H, Kirchen S, et al. Real-time PCR detection of *Pseudomonas aeruginosa* in clinical and municipal wastewater and genotyping of the ciprofloxacin-resistant isolates. *FEMS Microbiol Ecol* 2006;57. 158–167.
- [105] Poole K. Efflux-mediated resistance to fluoroquinolones in Gram-negative bacteria. *Antimicrob Agents Chemother* 2000;44. 2233–2241.
- [106] Wolter DJ, Smith-Moland E, Goering RV, et al. Multidrug resistance associated with *mexXY* expression in clinical isolates of *Pseudomonas aeruginosa* from a Texas hospital. *Diagn Microbiol Infect Dis* 2004;50. 43–50.
- [107] Zhanel GG, Hoban DJ, Schurek K, et al. Role of efflux mechanisms on fluoroquinolone resistance in *Streptococcus pneumoniae* and *Pseudomonas aeruginosa*. *Int J Antimicrob Agents* 2004;24. 529–535.
- [108] Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. *Drug Resist* 2010;13. 151–171.
- [109] Poole K. Aminoglycoside resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2005;49. 479–487.
- [110] Kettner M, Milosovic P, Hletkova M, et al. Incidence and mechanisms of aminoglycoside resistance in *Pseudomonas aeruginosa* serotype O11 isolates. *Infection* 1995;23. 380–383.
- [111] Kim JY, Park YJ, Kwon HJ, et al. Occurrence and mechanisms of *ami-kacin* resistance and its association with β -lactamases in *Pseudomonas aeruginosa*: a Korean nationwide study. *J Antimicrob Chemother* 2008;62. 479–483.
- [112] Jin JS, Kwon KT, Moon DC, et al. Emergence of 16S rRNA methylase *rmtA* in colistin-only-sensitive *Pseudomonas aeruginosa* in South Korea. *Int J Antimicrob Agents* 2009;33. 490–491.
- [113] Riccio ML, Pallecchi L, Fontana R, et al. In70 of plasmid pAX22, a *blaVIM-1*-containing integron carrying a new aminoglycoside phosphotransferase gene cassette. *Antimicrob Agents Chemother* 2001;45. 1249–1253.
- [114] Shaw KJ, Munayyer H, Rather PN, et al. Nucleotide sequence analysis and DNA hybridization studies of the *ant(4')-IIa* gene from *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 1993;37. 708–714.
- [115] Sabtcheva S, Galimand M, Gerbaud G, et al. Aminoglycoside resistance gene *ant(4')-IIb* of *Pseudomonas aeruginosa* BM4492, a clinical isolate from Bulgaria. *Antimicrob Agents Chemother* 2003;47. 1584–1588.

- [116] Miller GH, Sabatelli FJ, Naples L, et al. Resistance to aminoglycosides in *Pseudomonas*. Aminoglycoside Resistance Study Groups. Trends Microbiol 1994;2. 347–353.
- [117] Hachler H, Santanam P, Kayser FH. Sequence and characterization of a novel chromosomal aminoglycoside phosphotransferase gene, *aph* (3')-IIb, in *Pseudomonas aeruginosa*. Antimicrob Agents Chemother 1996;40. 1254–1256.
- [118] Sobel ML, McKay GA, Poole K. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in *Pseudomonas aeruginosa* clinical isolates. Antimicrob Agents Chemother 2003;47. 3202–3207.
- [119] Hocquet D, Nordmann P, El Garch, et al. Involvement of the MexXY- OprM efflux system in emergence of cefepime resistance in clinical strains of *Pseudomonas aeruginosa*. Antimicrob Agents Chemother 2006;50. 1347–1351.
- [120] Islam S, Oh H, Jalal S, et al. Chromosomal mechanisms of aminoglycoside resistance in *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. Clin Microbiol Infect 2009;15. 60–66.
- [121] Yamane K, Doi Y, Yokoyama K, et al. Genetic environments of the *rmtA* gene in *Pseudomonas aeruginosa* clinical isolates. Antimicrob Agents Chemother 2004;48. 2069–2074.
- [122] Zhou Y, Yu H, Guo Q, et al. Distribution of 16S rRNA methylases among different species of Gram-negative bacilli with high-level resistance to aminoglycosides. Eur J Clin Microbiol Infect Dis 2010;29. 1349–1353.
- [123] Gurung M, Moon DC, Tamang MD, et al. Emergence of 16S rRNA methylase gene *armA* and carriage of *bla*IMP-1 in *Pseudomonas aeruginosa* isolates from South Korea. Diagn Microbiol, Infect Dis 2010;68. 468–470.
- [124] Doi Y, Ghilardi AC, Adams J, et al. High prevalence of metallo- β -lactamase and 16S rRNA methylase coproduction among imipenem-resistant *Pseudomonas aeruginosa* isolates in Brazil. Antimicrob Agents Chemother 2007;51. 3388–3390.
- [125] Lincopan N, Neves P, Mamizuka EM, et al. Balanoposthitis caused by *Pseudomonas aeruginosa* co-producing metallo- β -lactamase and 16S rRNA methylase in children with hematological malignancies. Int J Infect Dis 2010;14. 344–347.
- [126] Mushtaq S, Ge Y, Livermore DL. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β -lactamases. Antimicrob Agents Chemother 2004;48. 1113–1119.
- [127] Dean CR, Visalli MA, Projan SJ, et al. Efflux-mediated resistance to tigecycline (GAR-936) in *Pseudomonas aeruginosa* PAO1. Antimicrob Agents Chemother 2003;47. 972–978.

- [128] Oie S, Fukui Y, Yamamoto M, et al. In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo β -lactamase-producing *Pseudomonas aeruginosa*. BMC Infect Dis 2009;9. 123.
- [129] Montero M, Horcajada JP, Sorli L, et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant *Pseudomonas aeruginosa* infections. Infection 2009;37. 461–465.
- [130] Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for micro-biologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010;35. 194–199.
- [131] Giamarellou H. Treatment options for multidrug-resistant bacteria. Expert Rev Anti Infect Ther 2006;4. 601–618.
- [132] Landman D, Bratu S, Alam M, et al. Citywide emergence of *Pseudomonas aeruginosa* strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother 2005;55. 954–957.
- [133] Abraham N, Kwon DH. A single amino acid substitution in PmrB is associated with polymyxin B resistance in clinical isolate of *Pseudomonas aeruginosa*. FEMS Microbiol Lett 2009;298. 249–254.
- [134] Barrow K, Kwon DH. Alterations in two-component regulatory systems of *phoPQ* and *pmrAB* are associated with polymyxin B resistance in clinical isolates of *Pseudomonas aeruginosa*. Antimicrob Agents Chemother 2009;53. 5150–5154.
- [135] Johansen HK, Moskowitz SM, Ciofu O, et al. Spread of colistin resistant non-mucoid *Pseudomonas aeruginosa* among chronically infected Danish cystic fibrosis patients. J Cyst Fibros 2008;7. 391–397.
- [136] Matthaiou DK, Michalopoulos A, Rafailidis PI, et al. Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: a matched case-control study. Crit Care Med 2008;36. 807–811.
- [137] Samonis G, Matthaiou DK, Kofteridis D, et al. In vitro susceptibility to various antibiotics of colistin-resistant Gram-negative bacterial isolates in a general tertiary hospital in Crete, Greece. Clin Infect Dis 2010;5. 1689–1691.
- [138] Moskowitz SM, Ernst RK, Miller SI. PmrAB, a two-component regulatory system of *Pseudomonas aeruginosa* that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J Bacteriol 2004;186. 575–579.
- [139] Ernst RK, Yi EC, Guo L, et al. Specific lipopolysaccharide found in cystic fibrosis airway *Pseudomonas aeruginosa*. Science 1999;286. 1561–1565.
- [140] Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 2009;69. 1879–1901.

- [141] Falagas ME, Giannopoulou KP, Kokolakis GN, et al. Fosfomycin: use beyond urinary tract and gastrointestinal infections. *Clin Infect Dis* 2008;46. 1069-1077
- [142] Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant *Pseudomonas aeruginosa* and *Acinetobacter* species. *Clin Infect Dis* 2006; 43. Suppl 2:S95-99.
- [143] Zuravleff JJ, Yu VL, Yee RB. Ticarcillin-tobramycin-rifampin: in vitro synergy of the triple combination against *Pseudomonas aeruginosa*. *J Lab Clin Med* 1983;101. 896–902.
- [144] Fish DN, Choi MK, Jung R. Synergic activity of cephalosporins plus fluoroquinolones against *Pseudomonas aeruginosa* with resistance to one or both drugs. *J Antimicrob Chemother* 2002;50. 1045–1049.
- [145] Gunderson BW, Ibrahim KH, Hovde LB, et al. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant *Pseudomonas aeruginosa* in an in vitro pharmacodynamic model. *Antimicrob Agents Chemother* 2003;47. 905–909.
- [146] Saiman L, Chen Y, San Gabriel P, et al. Synergistic activities of macrolides antibiotics against *Pseudomonas aeruginosa*, *Burkholderia cepacia*, *Stenotrophomonas maltophilia*, and *Alcaligenes xylosoxidans* isolated from patients with cystic fibrosis. *Antimicrob Agents Chemother* 2002;46. 1105–1107.
- [147] Perez Urena MT, Barasoain I, Espinosa M, et al. Evaluation of different antibiotic actions combined with rifampicin. *Chemotherapy* 1975;27. 82–89.
- [148] Chini NX, Scully B, DellaLatta P. Synergy of polymyxin B with imipenem and other antimicrobial agents against *Acinetobacter*, *Klebsiella*, and *Pseudomonas* species. Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology 1998; Abstract E-56.
- [149] Pankuch GA, Lin G, Seifect H, et al. Activity of meropenem with and without ciprofloxacin and colistin against *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2008;52. 333-336.